What is HC Wainwright's Forecast for HRMY FY2026 Earnings?

Key Points

• HC Wainwright lowered its FY2026 EPS forecast for Harmony Biosciences to $3.52 from $3.73, below the broader consensus estimate of $3.79.
• Despite the estimate reduction, HC Wainwright maintained a Buy rating and $55 price target. Analysts overall give HRMY a “Moderate Buy” consensus rating with an average target of $48.20.
• Harmony recently exceeded quarterly expectations, reporting $1.28 EPS and $261.28 million in revenue, with revenue rising 30.3% year over year.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Research analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Harmony Biosciences in a research note issued on Tuesday, October 27th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of $3.52 per share for the year, down from their previous estimate of $3.73. HC Wainwright has a "Buy" rating and a $55.00 price target on the stock. The consensus estimate for Harmony Biosciences' current full-year earnings is $3.79 per share.

Other research analysts also recently issued reports about the stock. Oppenheimer restated an "outperform" rating on shares of Harmony Biosciences in a research note on Thursday, September 24th. LADENBURG THALM/SH SH started coverage on shares of Harmony Biosciences in a research note on Thursday, October 15th. They set a "buy" rating and a $55.00 price target on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a $42.00 price target on shares of Harmony Biosciences in a research note on Thursday, October 1st. Zacks Research upgraded shares of Harmony Biosciences from a "hold" rating to a "strong-buy" rating in a report on Thursday, October 15th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $50.00 price objective on shares of Harmony Biosciences in a research report on Monday, October 19th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Harmony Biosciences currently has a consensus rating of "Moderate Buy" and an average target price of $48.20.

Harmony Biosciences Trading Up 1.4%

HRMY opened at $38.50 on Thursday. The firm has a market capitalization of $2.24 billion, a P/E ratio of 12.50, a P/E/G ratio of 0.29 and a beta of 1.01. The firm's 50 day moving average is $39.77 and its 200-day moving average is $34.72. Harmony Biosciences has a 52-week low of $25.90 and a 52-week high of $43.49. The company has a quick ratio of 3.45, a current ratio of 3.48 and a debt-to-equity ratio of 0.13.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $1.28 earnings per share for the quarter, topping analysts' consensus estimates of $0.96 by $0.32. Harmony Biosciences had a return on equity of 20.06% and a net margin of 18.88%. The firm had revenue of $261.28 million during the quarter, compared to analysts' expectations of $250.77 million. During the same quarter in the prior year, the business earned $0.92 EPS. Harmony Biosciences's quarterly revenue was up 30.3% compared to the same quarter last year.

Insider Transactions at Harmony Biosciences

In other Harmony Biosciences news, insider Kumar Budur sold 35,852 shares of the company's stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $43.05, for a total value of $1,543,428.60. Following the transaction, the insider directly owned 13,115 shares of the company's stock, valued at $564,600.75. This represents a 73.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last quarter, insiders sold 72,406 shares of company stock worth $3,108,520. 11.00% of the stock is owned by insiders.

Institutional Trading of Harmony Biosciences

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in shares of Harmony Biosciences in the 2nd quarter valued at approximately $258,583,000. venBio Partners LLC bought a new stake in shares of Harmony Biosciences in the 2nd quarter worth approximately $17,192,584. Tieton Capital Management LLC acquired a new position in Harmony Biosciences during the 2nd quarter valued at approximately $11,170,000. Bank of New York Mellon Corp acquired a new position in Harmony Biosciences during the 2nd quarter valued at approximately $9,937,000. Finally, Dimensional Fund Advisors LP grew its stake in Harmony Biosciences by 13.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,076,510 shares of the company's stock worth $58,157,000 after buying an additional 245,784 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company's stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial-stage biopharmaceutical company focused on developing and providing therapies for patients with rare neurological disorders. The company's activities center on conditions involving sleep-wake regulation and other central nervous system disorders where treatment options may be limited.

Harmony's principal product is WAKIX (pitolisant), an oral, non-scheduled treatment that acts as a histamine-3 receptor antagonist/inverse agonist. In the United States, WAKIX is approved for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy and for excessive daytime sleepiness in pediatric patients aged 6 and older with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.